H. Lundbeck boosts neurologic drug portfolio with Chelsea Therapeutics buy

05/9/2014 | Genetic Engineering & Biotechnology News

H. Lundbeck said it plans to purchase Chelsea Therapeutics for as much as $658 million. The acquisition, expected to be finalized next quarter, will give Lundbeck access to Chelsea's investigational neurologic disorder treatments and its FDA-approved neurogenic orthostatic hypotension drug Northera. The firms expect Northera to enter the market in the second half of 2014.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations